Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.
Nyxoah is under fresh scrutiny after analyst fair value estimates shifted from €9.0 to about €7.37 per share, an adjustment of roughly 18% that reflects a reset in price targets. Recent research links these cuts to more cautious assumptions around capital needs, valuation, and execution risk. At the same time, commentary still points to progress with the Genio launch and U.S. net revenue trends. As you read on, you will see how these changing targets, and the debate between bullish and bearish views, shape the evolving Nyxoah story and what to watch next.
Stay updated as the Fair Value for Nyxoah shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Nyxoah.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Piper Sandler, which cut its Nyxoah price target to US$7 from US$9, still uses an Overweight rating and highlights that the Genio launch and U.S. net revenue trends are in line with company expectations.
-
Piper Sandler also comments that Nyxoah has the potential to be a high growth asset, framing the current period as one where execution on the launch and revenue ramp are key drivers in their thesis.
🐻 Bearish Takeaways
-
Stifel has taken a more cautious stance on Nyxoah, reducing its price target twice, from US$5 to US$3 and issuing a Hold rating after updating its model for the recent capital raise.
-
Both Stifel and Piper Sandler point to capital needs. Piper notes that Nyxoah's balance sheet will likely need additional support. This feeds into debates around valuation and execution risk.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 3 risks for Nyxoah. See which could impact your investment.
How This Changes the Fair Value For Nyxoah
-
Fair value estimate adjusted from €9.0 to about €7.37 per share, a reduction of roughly 18%.
-
Forecast revenue growth revised from about 129.93% to about 104.93%.
-
Projected net profit margin moved from about 2.87% to about 4.92%.
-
Future P/E multiple updated from about 172.04x to about 73.41x.
-
Discount rate used in models shifted from 8.09% to about 6.89%.
Never Miss an Update: Follow The Narrative
Narratives connect Nyxoah's business story to the financial assumptions that sit behind fair value and analyst expectations. They update as new approvals, trial data, capital raises, or guidance reshape the company's outlook.
Head over to the Simply Wall St Community and follow the Narrative on Nyxoah to stay up to date on:
-
How FDA PMA approval for Genio and its differentiated label could help Nyxoah reach more obstructive sleep apnea patients in the U.S.
-
The impact of growing physician interest, expanding surgeon and sleep center networks, and reimbursement progress on future Genio adoption.
-
Key risks around legal disputes with competitors, high cash burn, reimbursement uncertainty, and the current limits of Genio's eligible patient pool.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NYXH.BR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
